Replies to post #831 on Rexahn Pharmaceuticals, Inc. (REXN)

[sons4]

Rexahn Pharma Initiated with a Buy Rating

Rexahn Pharmaceuticals Inc. (RNN, Free Analysis), a clinical stage biopharmaceutical company focused on cancer and CNS diseases, was initiated with a Buy rating and $3.00 per share price target by Brean Murray ahead of the opening bell. At a significant 144% premium to the current market price, the analyst’s price target reflects a very bullish stance on the company’s future outlook.

While the stock has been beaten down in recent months by Dr. Chang Ahn’s decision to step down from CEO and a recent dilutive capital raise, the biopharmaceutical company has made considerable progress in advancing its clinical trials and Ahn has been increasing his stake in the company. As a result, this is one stock that is potentially misunderstood by the market and could be a bargain at these levels.

[surf1944]

Hunting for the Next Dendreon

bought 40k shares in the past week, one of the few bio tech stocks that hasn't had a recent run

Rexahn Pharmaceuticals (RNN): Rexahn is a biopharmaceutical company that is engaged in the discovery and development of treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. RNN currently has a series of three Phase II clinical trials with drug candidates that have the potential to be real game changers. The first is a drug called Archexin which is an anticancer drug for the treatment of pancreatic cancer and renal cell carcinoma. When compared to conventional chemotherapy, Archexin blocks the production of a molecule that plays a central role in the uncontrolled growth of tumor mass. Therefore, Archexin may be able to replace the current standard cancer therapy with improved efficacy and tolerability. The world market for pancreatic cancer drugs is projected to exceed $1.2 billion by the year 2015. Top line results are expected sometime in the 2nd half of 2011. If ultimately accepted, RNN would find itself competing against rival therapies by Bayer and Onyx (ONXX) and Pfizer (PFE).

Serdaxin is another drug designed for the treatment of depression and neurodegenerative disorders. Data from a Phase IIa study shows that it improves symptoms of major depressive disorder. Serdaxin also promotes survival of neuronal cells in animal studies which suggests it may provide an innovative approach for the treatment of other brain conditions like Parkinson’s and Alzheimer’s diseases. The market for those two aliments is huge.

Zoraxel is a drug being developed for sexual dysfunction. Like the two mentioned above, it is another potential game-changing drug. Unlike other erectile dysfunction drugs targeting peripheral blood flow, Zoraxel boosts sexual functions by directly modulating specific brain activities. This mechanism gives Zoraxel a superior safety profile and promises increased patient satisfaction over standard medications such as Viagra. The Phase IIa clinical trial of Zoraxel has been completed with positive results and the Phase IIb trial is underway and will continue through 2010-11. The world market for erectile dysfunction drugs is projected to reach $4.4 billion by the year 2015. If RNN could actually bring Zoraxel to market and topple such medications as Viagra, the stock price would appreciate well above current levels.

In April of 2011 the company reported a cash position of $26 million and a monthly burn rate of $1.1 million. This cash position was supported when Rexahn announced it had received net proceeds of approximately $9.32 million when it sold an aggregate of 8.33 million shares of its common stock and warrants.

http://seekingalpha.com/article/278882-hunting-for-the-next-dendreon?source=yahoo